NCT02144428

Brief Summary

The management of children with confirmed cow's milk allergy is based on complete avoidance of cow's milk proteins and leaves the physician with several dietary options, none of which, given the prevalence, spectrum and potential seriousness of the condition, can be recommended to all patients. In the absence of an alternative to cow's milk, the management of cow's milk allergy is based on the use of safe, affordable and nutritionally adequate formulas. Extensively hydrolyzed cow's milk protein formulas, which are considered as safe for most children with cow's milk allergy, are still liable to contain residual peptides, and hypersensitivity reactions may occur in infants allergic to cow's milk protein. Thus, specific product allergenicity must be addressed on an individual basis before recommending a formula as a substitute for cow's milk. Soy-based formula can also concomitant sensitize cow's milk allergy children to soy. Amino acid-based formulas have been studied from safety and nutritional efficacy perspectives. These formulas have been proposed for subjects highly sensitive to cow's milk protein and that cannot be managed using extensively hydolyzed formula and for children with multiple food allergies. In these conditions aminoacid based formulas are able to effectively cure allergic symptoms and to improve body growth.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2011

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2011

Completed
3.1 years until next milestone

First Submitted

Initial submission to the registry

May 14, 2014

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 22, 2014

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2014

Completed
Last Updated

May 22, 2014

Status Verified

May 1, 2014

Enrollment Period

3.6 years

First QC Date

May 14, 2014

Last Update Submit

May 19, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of subjects with cow's milk allergy tolerant substitutive formulas

    Safety and tolerability of substitutive formulas

    At diagnosis and for at least 1 months after the diagnosis

Study Arms (1)

Cow's milk allergy

Subjcets with a sure diagnosis of cow'a milk allergy on exclusion diet

Eligibility Criteria

AgeUp to 36 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

Subjects with cow's milk allergy diagnosed by family pediatrician operating in Italy

You may qualify if:

  • subjects with a cow's milk allergy
  • age between 0 to 36 months

You may not qualify if:

  • age more than 36 months
  • eosinophilic disorders of the gastrointestinal tract,
  • food protein induced enterocolitic syndrome,
  • concomitant chronic systemic diseases,
  • congenital cardiac defects,
  • active tuberculosis,
  • autoimmune diseases,
  • immunodeficiency,
  • chronic inflammatory bowel diseases,
  • celiac disease,
  • cystic fibrosis,
  • metabolic diseases,
  • lactose intolerance,
  • malignancy,
  • chronic pulmonary diseases,
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Naples Federico II

Naples, 80131, Italy

RECRUITING

MeSH Terms

Conditions

Milk Hypersensitivity

Condition Hierarchy (Ancestors)

Food HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Central Study Contacts

Roberto Berni Canani, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD

Study Record Dates

First Submitted

May 14, 2014

First Posted

May 22, 2014

Study Start

April 1, 2011

Primary Completion

November 1, 2014

Study Completion

November 1, 2014

Last Updated

May 22, 2014

Record last verified: 2014-05

Locations